Calendar An icon of a desk calendar. Cancel An icon of a circle with a diagonal line across. Caret An icon of a block arrow pointing to the right. Email An icon of a paper envelope. Facebook An icon of the Facebook "f" mark. Google An icon of the Google "G" mark. Linked In An icon of the Linked In "in" mark. Logout An icon representing logout. Profile An icon that resembles human head and shoulders. Telephone An icon of a traditional telephone receiver. Tick An icon of a tick mark. Is Public An icon of a human eye and eyelashes. Is Not Public An icon of a human eye and eyelashes with a diagonal line through it. Pause Icon A two-lined pause icon for stopping interactions. Quote Mark A opening quote mark. Quote Mark A closing quote mark. Arrow An icon of an arrow. Folder An icon of a paper folder. Breaking An icon of an exclamation mark on a circular background. Camera An icon of a digital camera. Caret An icon of a caret arrow. Clock An icon of a clock face. Close An icon of the an X shape. Close Icon An icon used to represent where to interact to collapse or dismiss a component Comment An icon of a speech bubble. Comments An icon of a speech bubble, denoting user comments. Ellipsis An icon of 3 horizontal dots. Envelope An icon of a paper envelope. Facebook An icon of a facebook f logo. Camera An icon of a digital camera. Home An icon of a house. Instagram An icon of the Instagram logo. LinkedIn An icon of the LinkedIn logo. Magnifying Glass An icon of a magnifying glass. Search Icon A magnifying glass icon that is used to represent the function of searching. Menu An icon of 3 horizontal lines. Hamburger Menu Icon An icon used to represent a collapsed menu. Next An icon of an arrow pointing to the right. Notice An explanation mark centred inside a circle. Previous An icon of an arrow pointing to the left. Rating An icon of a star. Tag An icon of a tag. Twitter An icon of the Twitter logo. Video Camera An icon of a video camera shape. Speech Bubble Icon A icon displaying a speech bubble WhatsApp An icon of the WhatsApp logo. Information An icon of an information logo. Plus A mathematical 'plus' symbol. Duration An icon indicating Time. Success Tick An icon of a green tick. Success Tick Timeout An icon of a greyed out success tick. Loading Spinner An icon of a loading spinner.

Aberdeen Alzheimer’s drug on fast track for approval after trial found it slows progress of dread disease

The latest trial of a TauRX drug has show it can slow the progress of Alzheimer's disease.
The latest trial of a TauRX drug has show it can slow the progress of Alzheimer's disease.

A drug developed by researchers in Aberdeen has been put on a fast track programme for approval as trial results show it can slow the progress of Alzheimer’s disease.

TauRX Pharmaceuticals has hailed a “treatment breakthrough” in its third clinicial trial of the drug which involved almost 600 people with the devastating disease.

Alzheimer’s disease is the most common cause of dementia and causes people to experience memory loss and other cognitive difficulties.

It is set to affect more than a million Britons by the middle of this century, but its cause and thus its treatment is poorly understood.

Professor Claude Wischik, co-founder and executive chairman at TauRX, led the development of the drug after observing tau “tangles” in the brains of Alzheimer’s patients. Picture by Michal Wachucik/Abermedia

The firm’s co-founder Professor Claude Wischik, 72, first observed observed abnormal fibres of protein called tau causing “tangles” in the brains of Alzheimer’s patients over thirty years ago.

Having relocated from Cambridge to Aberdeen University in 1997, Mr Wischik co-founded TauRx along with late Singaporean investor, Dr KM Seng in 2002.

Previous trials of TauRX drugs showed little difference between the drug and a placebo.

In the latest 12-month, phase three trial, participants taking the drug hydromethylthionine mesylate (HMTM) experienced a slowdown in the rate of memory loss and other functional impairmens when compared to other sufferers of the disease.


Professor Wischik, who is a chair in mental health at Aberdeen University, said a full analysis of the data would be released at a later date but he would provide an update on progress at a global conference taking place in London next week.

He said the new drug was a significant innovation for a disease that has not seen any new treatments come to market for decades.

He said: “Today with limited treatments for Alzheimer’s, the standard of care does not impact the underlying causes of symptom progression.

Alzheimer’s remains one of the world’s greatest unmet medical needs.”

Professor Claude Wischik

“HMTM aims to significantly slow disease progression, providing longer term benefits compared to medications brought to market almost twenty years ago.”

He added:  “The output indicates that participants receiving HMTM decline at a rate substantially less than is typical in Alzheimer’s based on published research.

“This was seen for both cognitive and functional endpoints across a broad range of severity from mild cognitive impairment (MCI) to moderate Alzheimer’s.

“Importantly, the safety profile is favourable and consistent with previous studies.

“Our data analysis is ongoing and will be reported at a later date.

“We look forward to providing an update on our progress on 9th June 2022 at the 35th Global Conference of Alzheimer’s Disease International.”

On the fast track

Prior to the release of the interim data, the drug was awarded an “innovation passport” by the UK’s drug development regulator in order to speed it through becoming more widely available to people affected by the disease.

Medicines & Healthcare products Regulatory Agency (MHRA) granted the passport which is the first stage of its innovative licensing and access lpathway (Ilap) designed to accelerate development and approval times for new drugs.

Professor Wischik said: “The Ilap designation represents a clear signal of regulatory support for a prospective treatment breakthrough in Alzheimer’s, which remains one of the world’s greatest unmet medical needs.

“Dementia is a leading cause of death around the world, and the innovation passport, as the first stage of the ILAP scheme, enables access to the collaborative approach of regulators and associated health technology assessment bodies to both drug licensing and access throughout the UK.”

Read: Aberdeen researchers developing blood test to show Alzheimer’s risk

Already a subscriber? Sign in





Please enter the name you would like to appear on your comments. (It doesn’t have to be your real name - but nothing rude please, we are a polite bunch!) Use a combination of eight or more characters that includes an upper and lower case character, and a number.

By registering with [[site_name]] you agree to our Terms and Conditions and our Privacy Policy

Or sign up with

Facebook Google



Or login with

Forgotten your password? Reset it